Clinical Trial

Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will be conducted to evaluate the efficacy and safety of GZR101-80 Injection in patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs or Basal Insulin.
Protocol Amendment History 3 changes
notable Enrollment increased: 300 -> 345 participants 2026-04-16
notable Primary completion moved earlier: 2027-04-22 -> 2027-02-11 2026-04-16
minor Completion pushed: 2027-08-17 -> 2027-09-23 2026-04-16
Trial Details
NCT Number NCT07387003
Lead Sponsor Gan & Lee Pharmaceuticals.
Conditions Type 2 Diabetes (T2DM)
Enrollment 345 participants
Start Date 2026-04-10
Primary Completion 2027-02-11 (estimated)
Study Completion 2027-09-23 (estimated)
Updated on ClinicalTrials.gov 2026-04-15